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ition. The follow-up was done in databases Pharmaca Fennica
(1994–2003), SLD Pharma (1993–2002), SLD Nordic
(1998–2003) and SLD Price (1997–2003). Nominal and ofﬁcial
Consumer Price Index (Statistics Finland) adjusted (real) retail
prices (RP; including 8% VAT) were used. RESULTS: From 1993
to 2003, we identiﬁed 111 marketing companies, 1196 active
substances, 2515 trade names (products) and 9606 packages. In
1994 altogether 19 marketers introduced 32 NCE’s, of which
13% (4/32) were combination products. Some 87% (28/32) of
NCE’s, and 70% (42/60) of packages survived till the end of the
follow-up period. From 1994 to 2003 mean package RP
decreased 19% in nominal and 30% in real prices. Real prices
decreased 32% in No Refund, 31% in Basic (50%), 19% in
Lower (75%) Special and 22% in Higher (100%) Special Refund
categories. CONCLUSIONS: In 1994 Finland became a member
of the European Economic Area. Since then, retail prices have
decreased markedly in Finland even before the introduction of
generic and parallel import substitution. The observed 30%
decrease in real retail prices among the survival cohort suggests
that medicines have clearly become more cost-effective.
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OBJECTIVES: Anticoagulants are widely used and represent a
class of drugs that are problem-prone and have a high potential
for adverse patient outcomes. As such, these drugs may be
amenable to the use of prescribing guidelines. However, rela-
tively little has been published on the effect of such guidelines
on clinical outcomes or costs of care. The purpose of this study
was to assess whether guidelines improve the appropriateness of
prescribing, clinical outcomes, and the costs associated with use
of anticoagulants in a sample of community hospitals in the
United States. METHODS: A retrospective analysis was per-
formed of data voluntarily collected by 15 hospitals before
(July–September 2001) and after (March–May 2002) implemen-
tation of anticoagulant prescribing guidelines. Statistical 
analyses of both patient-level and hospital-level variables were
conducted. RESULTS: Implementation of the guidelines resulted
in a signiﬁcant increase in the proportion of anticoagulants that
were prescribed appropriately (59.8% v. 86.9%, p < 0.001). The
guidelines also resulted in a shift in the type of anticoagulants
prescribed (decreased use of unfractionated heparin and
increased use of low-molecular-weight heparins). There was sug-
gestive evidence, though not statistically signiﬁcant, that the
guidelines resulted in fewer anticoagulant-associated adverse
events (total bleeding RR = 0.71) and lower costs (savings of
$56.15 per patient per day). CONCLUSIONS: While limitations
existed with the study design, sufﬁcient beneﬁts were identiﬁed
to warrant hospitals to consider use of these or similar guide-
lines on a routine basis. Clearly, additional study in this area
would be useful.
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Methadone maintenance programs (MMP) are used to treat
opioid addiction. In Spain, there are currently no practice guide-
lines available in MMP. OBJECTIVES: The present study reports
the use of a Delphi process to develop consensus regarding spe-
ciﬁc recommendations to include in MMP guidelines for use in
Catalonia, Spain. METHODS: The ﬁrst draft of the guidelines
were reviewed to determine where recommendations might be
needed but for which evidence was lacking in the literature, and
to generate potential items for inclusion in the Delphi question-
naire. Potential items were revised by guideline authors to agree
on ﬁnal inclusion and wording. These were included in a ques-
tionnaire administered in a three round Delphi process to
develop consensus on their inclusion in the guidelines as recom-
mendations. Panelists (n = 26) were a multidisciplinary group,
and all experts in MMP. A 4-point response option was used,
and when consensus was reached on a given item it was omitted
from the following Delphi rounds. All responses were anony-
mous and questionnaire administration was by e-mail and fax.
RESULTS: The questionnaire administered in the ﬁrst round of
the Delphi process consisted of 32 items formulated as recom-
mendations and grouped into four sections: “Entry, follow-up
and ﬁnalization of MMP” (16 items) “Take home” (5 items),
methadone in pregnancy (3 items), and “other aspects” (8 items).
In the ﬁrst round, consensus was reached on 17 of the 32 items;
in the second round, on 7 items and in the third round on 4
items. In total, consensus was reached for 28 of the 32 potential
recommendations initially included. A total of 23 recommenda-
tions deriving from the Delphi process were included in the
guidelines. CONCLUSIONS: The Delphi technique was useful
in obtaining expert consensus on recommendations to be
included in these guidelines, when evidence supporting recom-
mendations was not available in the literature.
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OBJECTIVES: To model the perspective of the generic drug
market in France over the 2004–2008 period, given the rapidly
increasing generic substitution rate and arrival on that market of
a large number of best-selling drugs. METHODS: We simulated
the development of the drug market under two sets of hypothe-
sis. In the ﬁrst hypothesis, we considered only the 129 molecules
which are presently available on the generic market and we froze
the substitution rate at the level reached in 2003. In the second
hypothesis we considered the 56 additional molecules, the patent
of which will expire between 2004 and 2008 and we extrapo-
lated the increase of the substitution rate observed over the last
years. We used Box-Jenkins technique to model the market evo-
lution. We made the assumption that generic ex-factory price will
be 40% below the princeps price. We ﬁnally computed the yearly
and aggregated difference between the two scenarios, from a
global market perspective and from the Health Insurance per-
spective taking into account the reimbursement rate of each 
compound. RESULTS: Over the considered period, the patent of
some of the best-selling drugs such as omeprazole, pravastatine,
simvastatine, etc. will expire. All together these drugs represent
15% of the 2003 reimbursed drug market. The substitution rate
will reach 80%, 4 years after patent expiration. This will result
in saving Health Insurance an estimated 1 billion Euro per year
as soon as 2006. The aggregated savings on the full period will
be above ﬁve billion Euros. Two-thirds of the savings will be
attributable to the new generic drugs. CONCLUSIONS: The
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generic revolution is still ahead and the drug market as a whole
will be deeply affected by an increasing number of generic drugs.
Public policy should take into account this evolution, in order to
maintain the industry capacity to innovate.
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OBJECTIVES: The number of economic evaluation studies has
grown extensively in recent years. However, a limited number of
studies investigated its impact on decision making; the gap is par-
ticularly evident in Italy where there are no such studies avail-
able. Objective of the research is to evaluate impact of economic
evaluation analysis on decision making in the Italian health care
system. The prospective taken is that of professionals operating
within the system. The aim is to investigate whether there are
evident differences in attitudes among professionals who conduct
different types of activities. METHODS: A 12 item based ques-
tionnaire was sent to 374 health care professionals who had
undergone some form of health economics training. The sample
was taken from a list of participants of a major health care man-
agement program at Bocconi School of Management in the last
10 years. RESULTS: Response rate was 35%. All respondents
stated that basics of economic evaluation analysis must be part
of the overall knowledge of health care professionals. Grade of
usefulness of these arguments in professional activities was rated
3.84 (scale 1–5). Respondents considered that economic evalua-
tion is more largely used in making managerial types of decisions
rather than clinical ones (mean 2.94 vs. 2.73). Decisions taken
according to short-term perspectives are considered the major
barrier in the use of economic evaluation studies, particularly 
by managers (71%). More training in health economics was 
indicated as the most relevant facilitating factor for a wider use
of studies, by both clinicians and managers (64%). Majority of
respondents (80%) considered that the maximum beneﬁts of eco-
nomic evaluation are taken from its use at the organizational
level. CONCLUSIONS: Although economic evaluation has a
rather modest impact on decision making in Italian health care,
there are some encouraging signs that could lead to its wider and
more effective use.
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OBJECTIVES: In Korea, even non-prescription drugs have been
on the list of reimbursable drugs, but recent suggestions are that
there is a need to change the scope of the positive list. In April
2002, 829 non-prescription alimentary tract drugs were removed
from the list of reimbursable drugs and made non-reimbursable
even when doctors prescribed them. This study investigated the
effect of delisting on the prescribing pattern of alimentary tract
drugs. METHODS: Health insurance reimbursement claims data
before (October 2001) and after (October 2002, October 2003)
the delisting were analyzed for 707 clinics (4% randomized sam-
pling). We calculated the prescription rate of alimentary tract
drugs and examined the use of alimentary tract drugs by dis-
eases. RESULTS: The prescription rate for alimentary tract drugs
declined from 79.03% in October 2001 to 59.91% in October
2002 and to 61.58% in October 2003. The prescription rate for
digestives, of which all products were delisted, dropped sharply
from 32.03% before delisting to 1.9% in October 2002 and to
0.75% in October 2003. Medicines for intestinal disorders were
prescribed less frequently after delisting, while the prescription
rate for anti-ulcerants and antacids increased by 3–4%. In
general, the drugs on the positive list were not switched to
delisted drugs, even though some listed ingredients were used
more often. Also, the use of alimentary tract drugs for patients
who had respiratory diseases such as common cold reduced more
than by 20% after delisting, while the prescription rate for those
with gastric ulcer decreased by 1% after delisting. CONCLU-
SIONS: The delisting policy reduced the use of alimentary tract
drugs. But there was difference in the effect of  delisting by drug
classiﬁcation and some delisted drugs were found to be switched
to listed drugs. The use of alimentary tract drugs changed less
for diseases for which they are essential than for supplementary 
purposes.
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OBJECTIVES: The Dutch Ministry of Health (MoH) has
requested the Health Care Insurance Board (CVZ) to advise on
the modernisation of the drug reimbursement system
(Geneesmiddelenvergoedingssysteem GVS). On behalf of the
CVZ, PharMerit assessed the impact of market competition on
pricing and reimbursement (P&R) of patented drugs in Belgium,
France and Germany. METHODS: In-depth interviews with
reimbursement policy-makers; analysis of laws and policy docu-
ments. Impact of market competition (deﬁned as total number
of marketed generics and therapeutically comparable patented
drugs) on drug reimbursement decision-making was assessed in
each of the study countries. RESULTS: In Belgium and France,
drug P&R is determined in negotiation between manufacturers
and authorities. Generic prices are set 30–40% lower than spe-
cialties. “Late-arrivals” (e.g. me-too’s or other therapeutically
comparable patented drugs) receive lower prices than (ﬁrst-in-
class) “early-arrivals”. Since 2004, patented drugs in Germany
are no longer excluded from therapeutic reference-pricing if at
least 3 comparable alternatives are available. Sickness Funds are
legally entitled to adjust cluster reference prices in case justiﬁed
by “changes in the market”. Cluster reference prices with a high
number of generics (off-patent and patented drugs) are expected
to be reduced in the future. Prices of patented late-arrivals in The
Netherlands are not directly subject to market competition con-
siderations and tend to level the cluster reference price, based 
on the average price of clustered products. Recently, prices of
generics have been lowered in an informal agreement between
MoH and manufacturers. The MoH is seeking ways to mod-
ernise the reimbursement system. CONCLUSIONS: In Belgium
and France, late-arriving patented drugs can be assigned rela-
tively lower prices in comparison to their early-arriving com-
petitors. In Germany, introduction of late-arrivals may impact
on P&R of both early and late-arrivals. In the current set-up of
the Dutch GVS, market introduction of late-arrivals does not
impact on cluster reference prices.
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OBJECTIVES: Reimbursement policies clearly affect the ratio-
nal use of drugs. In Turkey there are three state funded social
